This morning, Informativos Telecinco featured our work at IR Sant Pau on a new class of protein-based nanoparticles engineered to home in on CXCR4+ tumor cells that drive metastasis while sparing healthy tissues. As Dr. Ugutz Unzueta explained during the segment, this selectivity aims to boost the effective dose at the tumor site and reduce systemic side effects—two chronic limitations of conventional chemotherapy.
The broadcast coincided with International Cancer Research Day, underscoring how advances in receptor-guided delivery and multivalent nanoparticle design may help us move beyond one-size-fits-all cytotoxic regimens toward truly precision nanomedicine. Our team’s approach builds on a decade of research targeting the CXCR4 axis—implicated in tumor dissemination—using modular, self-assembling protein carriers to concentrate payloads in high-risk cancer cell subpopulations. Recent reviews and studies continue to highlight CXCR4’s role in metastasis and therapy resistance, reinforcing the clinical rationale for targeted strategies like ours
